Sugi Predict

Sugi Predict / Compounds / SCHEMBL356638

SCHEMBL356638

SCHEMBL356638

O=C(Nc1ccccc1)c1c(F)cccc1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.55
▸ SMN1; SMN2 Q16637 6/20 0.55
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ HTT P42858 4/20 0.55
▸ LMNA P02545 3/20 0.55
▸ POLB P06746 2/20 0.53
▸ GAA P10253 3/20 0.53
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ JAK2 O60674 1/20 0.51
▸ JAK1 P23458 1/20 0.51
▸ TYK2 P29597 1/20 0.51
▸ NOD2 Q9HC29 1/20 0.51
▸ CXCR1 P25024 1/20 0.51
▸ CXCR2 P25025 1/20 0.51
▸ MDM2 Q00987 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.49
▸ NCOA1 Q15788 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15597616 0.86 GAA (0.54) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL30739792 0.84 KMT2A (0.57) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL2771172 0.84 LMNA (0.73) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL2021784 0.84 MEN1 (0.65) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL16583251 0.82 TDP1 (0.65) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL30739749 0.82 JAK2 (0.71) SMN1; SMN2MEN1KMT2AHTTLMNA
SCHEMBL21174680 0.82 MEN1 (0.54) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL20999385 0.81 MDM2 (0.45) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL5237553 0.81 KCNMA1 (0.58) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL16108922 0.80 ABCG2 (0.47) MAPTSMN1; SMN2MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3943494-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2022-01-26 — — EP claimed
US-10906907-B2 Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof ICOS CORPORATION (US) 2021-02-02 — — US claimed
CN-108409674-A A kind of preparation method of Ai Dailalisi intermediates 南京法恩化学有限公司 2018-08-17 — — CN claimed
CN-104130261-B The synthetic method of Chinese mugwort Delibes Shandong Kang Meile Pharmaceutical Technology Co., Ltd (CN) 2016-03-02 — — CN claimed
EP-3943494-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2022-01-26 — — EP disclosed
EP-3943494-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2022-01-26 — — EP disclosed
US-20210332047-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORP (US) 2021-10-28 — — US disclosed
CN-106232602-B Deuterated quinazolinone compound and pharmaceutical composition containing same 苏州泽璟生物制药股份有限公司 2021-06-18 — — CN disclosed
CN-104817559-B Deuterated quinazolinone compound and pharmaceutical composition containing same 苏州泽璟生物制药股份有限公司 2021-05-25 — — CN disclosed
EP-3153514-B1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORP (US) 2021-04-21 — — EP disclosed
US-10906907-B2 Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof ICOS CORPORATION (US) 2021-02-02 — — US disclosed
US-10870650-B2 Process for the preparation of amorphous idelalisib NATCO PHARMA LIMITED (IN) 2020-12-22 — — US disclosed
US-20100256168-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2010-10-07 — — US disclosed
US-20100256168-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION 2010-10-07 — — US disclosed
US-20080275067-A1 Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta ICOS CORPORATION (US) 2008-11-06 — — US disclosed
US-20080275067-A1 Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta ICOS CORPORATION (US) 2008-11-06 — — US disclosed
US-20080275067-A1 Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta ICOS CORPORATION (US) 2008-11-06 — — US disclosed
EP-1761540-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2007-03-14 — — EP disclosed
WO-2005113554-A2 METHOD OF PREPARING 3-PHENYL-2-[9H-PURIN-6-YLAMINO)-METHYL]-3H-QUINAZOLIN-4-ONE AND SUBSTITUTED AND RELATED COMPOUNDS ICOS CORPORATION (US) 2005-12-01 — — WO disclosed
WO-2005113556-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2005-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256168-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PI4KA MAPT 4423/4885SMN1; SMN2 4256/4885MEN1 4274/4885
US-10870650-B2 Process for the preparation of amorphous idelalisib IDE, PDE8B, PCSK9 MAPT 396/4885SMN1; SMN2 1053/4885MEN1 1704/4885
US-20080275067-A1 Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta PIK3CD, PIK3CA, PI4KA MAPT 4423/4885SMN1; SMN2 4256/4885MEN1 4274/4885
US-20210332047-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PI4KA MAPT 4423/4885SMN1; SMN2 4256/4885MEN1 4274/4885
US-10906907-B2 Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof PIK3CD, PIK3CA, PIK3CB MAPT 4218/4885SMN1; SMN2 4538/4885MEN1 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.